Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

25.71
-0.0700-0.27%
Volume:191.45K
Turnover:4.92M
Market Cap:2.66B
PE:-7.54
High:26.00
Open:25.47
Low:25.47
Close:25.78
52wk High:28.23
52wk Low:8.20
Shares:103.41M
Float Shares:95.05M
Volume Ratio:0.78
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:6.60
PE(LYR):-8.43

Loading ...

Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg

Reuters
·
Jun 08

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

GlobeNewswire
·
Jun 08

Nurix Therapeutics Chief Legal Officer Christine Ring sells 8,148 shares for $135,226.72

Reuters
·
Jun 03

Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG

Dow Jones
·
May 18

Nurix Therapeutics Shareholders Back Directors and Governance Proposals

TIPRANKS
·
May 16

Nurix Therapeutics shareholders ratify PwC as auditor for fiscal 2026

Reuters
·
May 16

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

GlobeNewswire
·
May 15

Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer

TIPRANKS
·
May 13

Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
May 13

Nurix CEO Sands to join RBC Global Healthcare Conference fireside chat

Reuters
·
May 13

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation

Reuters
·
May 13

Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026

Reuters
·
May 13

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

THOMSON REUTERS
·
May 13

Nurix CFO Hans van Houte disposes of common shares worth $233,463.29

Reuters
·
May 06

Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205

Reuters
·
May 05

Is Nurix’s Pan-Mutant BRAF Degrader Data Reshaping The Investment Case For Nurix Therapeutics (NRIX)?

Simply Wall St.
·
May 03

Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435

Reuters
·
May 02

Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 27

Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 23